Nanomedicine targeting ferroptosis to overcome anticancer therapeutic resistance
- PMID: 37728804
- DOI: 10.1007/s11427-022-2340-4
Nanomedicine targeting ferroptosis to overcome anticancer therapeutic resistance
Abstract
A potential reason for the failure of tumor therapies is treatment resistance. Resistance to chemotherapy, radiotherapy, and immunotherapy continues to be a major obstacle in clinic, resulting in tumor recurrence and metastasis. The major mechanisms of therapy resistance are inhibitions of cell deaths, like apoptosis and necrosis, through drug inactivation and excretion, repair of DNA damage, tumor heterogeneity, or changes in tumor microenvironment, etc. Recent studies have shown that ferroptosis play a major role in therapies resistance by inducing phospholipid peroxidation and iron-dependent cell death. Some ferroptosis inducers in combination with clinical treatment techniques have been used to enhance the effect in tumor therapy. Notably, versatile ferroptosis nanoinducers exhibit an extensive range of functions in reversing therapy resistance, including directly triggering ferroptosis and feedback regulation. Herein, we provide a detailed description of the design, mechanism, and therapeutic application of ferroptosis-mediated synergistic tumor therapeutics. We also discuss the prospect and challenge of nanomedicine in tumor therapy resistance by regulating ferroptosis and combination therapy.
Keywords: cancer therapy; ferroptosis; nanoinducers; therapy resistance.
© 2023. Science China Press.
Similar articles
-
Nanomedicine-mediated ferroptosis targeting strategies for synergistic cancer therapy.J Mater Chem B. 2023 Feb 8;11(6):1171-1190. doi: 10.1039/d2tb02161g. J Mater Chem B. 2023. PMID: 36650960 Review.
-
Ferroptosis in cancer therapy: a novel approach to reversing drug resistance.Mol Cancer. 2022 Feb 12;21(1):47. doi: 10.1186/s12943-022-01530-y. Mol Cancer. 2022. PMID: 35151318 Free PMC article. Review.
-
Recent research progress based on ferroptosis-related signaling pathways and the tumor microenvironment on it effects.Eur J Med Chem. 2024 Apr 5;269:116290. doi: 10.1016/j.ejmech.2024.116290. Epub 2024 Mar 7. Eur J Med Chem. 2024. PMID: 38518522 Review.
-
Inorganic Nanomedicine-Mediated Ferroptosis: A Synergistic Approach to Combined Cancer Therapies and Immunotherapy.Cancers (Basel). 2024 Sep 20;16(18):3210. doi: 10.3390/cancers16183210. Cancers (Basel). 2024. PMID: 39335181 Free PMC article. Review.
-
Ferroptosis Nanomedicine: Clinical Challenges and Opportunities for Modulating Tumor Metabolic and Immunological Landscape.ACS Nano. 2023 Aug 22;17(16):15328-15353. doi: 10.1021/acsnano.3c04632. Epub 2023 Aug 13. ACS Nano. 2023. PMID: 37573530 Review.
Cited by
-
The p38/MAPK pathway as a therapeutic target to prevent therapeutic escape of breast cancer stem cells.Sci China Life Sci. 2024 Sep;67(9):1867-1880. doi: 10.1007/s11427-023-2585-5. Epub 2024 Jun 26. Sci China Life Sci. 2024. PMID: 38951428
-
Engineering biomimetic nanosystem targeting multiple tumor radioresistance hallmarks for enhanced radiotherapy.Sci China Life Sci. 2024 Jul;67(7):1398-1412. doi: 10.1007/s11427-023-2528-5. Epub 2024 Apr 7. Sci China Life Sci. 2024. PMID: 38602587
-
Targeting the interplay of cGAS-STING and ferroptosis by nanomedicine in the treatment of cancer.J Exp Clin Cancer Res. 2025 Aug 22;44(1):249. doi: 10.1186/s13046-025-03520-6. J Exp Clin Cancer Res. 2025. PMID: 40846966 Free PMC article. Review.
-
Ferroptosis in liver cancer: a key role of post-translational modifications.Front Immunol. 2024 Apr 8;15:1375589. doi: 10.3389/fimmu.2024.1375589. eCollection 2024. Front Immunol. 2024. PMID: 38650929 Free PMC article. Review.
-
Early-onset and later-onset cancer: trends, risk factors, and prevention in Northern China.Sci China Life Sci. 2024 Sep;67(9):1928-1940. doi: 10.1007/s11427-023-2523-5. Epub 2024 May 23. Sci China Life Sci. 2024. PMID: 38809499
References
-
- Cao, K., Du, Y., Bao, X., Han, M., Su, R., Pang, J., Liu, S., Shi, Z., Yan, F., and Feng, S. (2022b). Glutathione-bioimprinted nanoparticles targeting of N6-methyladenosine FTO demethylase as a strategy against leukemic stem cells. Small 18, 2106558. - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical